Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating enzalutamide in chemotherapy-naïve, symptomatic metastatic castration-resistant prostate cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: WITHDRAWN